OGEN Oragenics, Inc.
Price Chart
Executive Summary
Oragenics, Inc. announced it is exploring potential acquisitions of CNS-focused assets that align with its proprietary intranasal delivery platform, as part of a broader strategy to expand its brain health pipeline. The move is strategic and forward-looking, but no definitive agreements have been reached.
Actionable Insight
Monitor for future announcements regarding asset acquisitions or partnerships; any material deal could significantly impact the company’s valuation given its small market cap ($4M). However, near-term impact is limited due to lack of concrete terms.
Key Facts
- Oragenics is exploring discussions with third parties for potential acquisition of CNS assets focused on brain health and recovery.
- No definitive agreements have been reached; there is no assurance any deal will be completed.
- The initiative is separate from its AI-driven partnership with Receptor.AI.
- The company continues to advance its lead candidate ONP-002 through Phase IIa trials in Australia, with U.S. Phase IIb trials planned for 2027.
- ONP-002 targets concussion and mild traumatic brain injury, with no FDA-approved pharmacological treatments currently available.
Financial Impact
No financial impact at this stage — exploratory discussions only, no transaction details disclosed.
Risk Factors
- No assurance that any acquisition will be completed.
- Execution risk in integrating new assets, should a deal occur.
- Limited financial resources may constrain ability to close or fund post-acquisition development.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253753 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 20, 2026
25d ago
|
DEFA14A
| $0.5900 $0.6100 | ▲ +3.39% | ▲ +1.54% | $0.6200 (+5.08%) |
|
May 19, 2026
26d ago
|
8-K
| $0.5700 $0.5999 | ▲ +5.25% | ▲ +3.00% | $0.6200 (+8.77%) |
|
May 7, 2026
5w ago
|
8-K
| $0.6100 $0.5700 | ▼ −6.56% | ▼ −8.06% | $0.6200 (+1.64%) |
|
Apr 13, 2026
8w ago
|
8-K
| $0.6800 $0.7100 | ▲ +4.41% | ▲ +1.12% | $0.6200 (−8.82%) |
|
Mar 25, 2026
11w ago
|
Press Release
| $0.5800 $0.5600 | ▲ +3.45% | ▲ +5.08% | $0.6200 (−6.90%) |
|
Mar 23, 2026
12w ago
|
EFFECT
| $0.6800 $0.5000 | ▼ −26.47% | ▼ −22.91% | $0.6200 (−8.82%) |
|
Mar 11, 2026
13w ago
|
8-K
| $0.9600 $0.7500 | ▼ −21.88% | ▼ −20.90% | $0.6200 (−35.42%) |
|
Mar 11, 2026
13w ago
|
Press Release
| $0.8800 $0.7900 | ▼ −10.23% | ▼ −8.04% | $0.6200 (−29.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access